Publications by authors named "M Willheim"
Article Synopsis
- The ELIMINATE project aimed to reconnect individuals in Eastern Austria with previously documented hepatitis C virus (HCV) infections to medical care, supporting global elimination goals set by the WHO.
- Researchers reviewed lab records from 2008 to 2020, identifying 5,695 individuals, but faced challenges such as 34% having died and 13% lacking contact information.
- Ultimately, they successfully contacted 617 individuals, leading to a 64.3% treatment initiation rate, and confirmed an HCV cure in 326 people, demonstrating the effectiveness of targeted outreach strategies in addressing HCV.
Article Synopsis
- The study aimed to use existing laboratory records to identify and treat individuals with hepatitis C virus (HCV) viremia, assisting in broader global elimination efforts.
- Out of 22,682 individuals who tested for HCV-RNA, 6006 had detectable viremia; barriers like invalid contact information hindered follow-up, but efforts led to successful treatment initiation in some.
- This interim report from the ELIMINATE project highlights the potential of systematic screening and recall, identifying a significant number of people previously lost to care who began antiviral treatment.
New commercially available point-of-care (POC) immunodiagnostic tests are appearing, which may yield rapid results for anti-SARS-CoV-2 antibodies. The aim of this study was to evaluate the diagnostic accuracy of rapid antibody detection tests compared to a validated laboratory-based enzyme-linked immunosorbent assay (ELISA) and to investigate infections amongst healthcare workers (HCWs) after unprotected close contact to COVID-19 patients. Blood serum and whole blood of 130 participants were tested with NADAL COVID-19 IgG/IgM rapid test and mö-screen 2019-NCOV coronavirus test against a validated ELISA test.
View Article and Find Full Text PDFFuture progress in the treatment of multiple myeloma (MM) requires both the characterisation of key drivers of the disease and novel, innovative approaches to tackle these vulnerabilities. The present study focussed on the pre-clinical evaluation of a novel drug class, BMI-1 modulators, in MM. We demonstrate potent activity of PTC-028 and PTC596 in a comprehensive set of in vitro and in vivo models, including models of drug resistance and stromal support.
View Article and Find Full Text PDF